A Valneva chikungunya vaccine under regulatory scrutiny for much of this year amid safety concerns is now no longer permitted for sale in the U.S. market. The FDA has suspended the biologics license of the vaccine, Ixchiq, following new reports of safety problems.

According to Valneva , the FDA cited four new reports of serious adverse events that were consistent with chikungunya-like illness. The Saint Herblain, France-based vaccine maker said Monday that suspension of the license requires the company to stop shipping and selling Ixchiq in the U.S. immediately.

Chikungunya is a mosquito-borne virus that circulates in tropical and subtropical regions. The virus can lead to Infection that causes fever, headache, and joint and muscle pain. Ixchiq is comprised of a live but weakened vers

See Full Page